Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
Lung Large Cell Carcinoma
Explore 15 assets in Lung Large Cell Carcinoma →Floatz Rating
CCC49/100
Confidence
Indicative
Sponsor
Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
34High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00673049CT.gov Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer | — | Terminated | — | — | — |
NCT00596830CT.gov Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Large Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer (this asset) | Pfizer | P3 | CCC · 49 |
| Carboplatin | National Cancer Institute (NCI) | P4 | A |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BBB |
| Etoposide | Barbara Ann Karmanos Cancer Institute | P3 | BBB |
| Gefitinib | National Cancer Institute (NCI) | P3 | BB |
| Vinorelbine Ditartrate | AIO-Studien-gGmbH | P3 | BB |
| Docetaxel | Korean South West Oncology Group | P3 | BB |
| Cetuximab | SWOG Cancer Research Network | P3 | BB |
| Shark Cartilage Extract | National Cancer Institute (NCI) | P3 | BB |
+23 more in the Lung Large Cell Carcinoma cohort
Other indications for Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P2 | CCC · 51 |
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 50 |
| Prostate Neoplasm | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer in Lung Large Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g2-anti-human-insulin-like-growth-factor-i-receptor-human-monoclonal-cp-751871-clone-2132-heavy-chain-disulphide-with-human-monoclonal-cp-751871-clone-2132-light-chain-dimer-lung-large-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →